KARO PHARMA AB Action · SE0007464888 · A14YW4 (XSTO) — cotations en temps réel, données d'entreprise, dividendes, fondamentaux et analyse de portefeuille IA sur MoneyPeak

Karo Pharma AB (publ) develops and markets prescription drugs and over-the-counter products for pharmacies and retail sector in Sweden, Norway, Denmark, Finland, France, Germany, Italy, rest of Europe, the United States, and internationally. It offers skin health products under the Remescar, Locobase, Decubal, and indy beauty brand names; intimate health products under the Pevaryl, Multi Gyn, Asan, and Selexid brand names; and foot health products under the Pevaryl, CCS, Nailner, and wortie brands. The company also provides pain, cough, and cold products under the Paracet, Ibux, Mollipect, and Viruseptin brand names; prescription drugs under the Burinex, Centyl, Kaleorid, and Lithionit brands; and wellness products under the nutravita, Alpha Foods, Flux, Allévo, Dosett, Dax, and Lactocare brands. It sells its products in approximately 90 countries with Europe and the Nordic region markets through direct sales organizations and a network of distributors, as well as online. The company was formerly known as Karo Bio AB (publ) and changed its name to Karo Pharma AB (publ) in March 2016. Karo Pharma AB (publ) was incorporated in 1987 and is headquartered in Stockholm, Sweden.